Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
Open Access
- 9 May 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 259 (11), 2401-2413
- https://doi.org/10.1007/s00415-012-6513-7
Abstract
Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. The present study evaluated the effect of atorvastatin added to interferon beta-1b in multiple sclerosis (MS) in a multicenter, randomized, parallel-group, rater-blinded study performed in eight Swiss hospitals. Seventy-seven patients with relapsing-remitting MS started interferon beta-1b every other day. After 3 months, they were randomized 1:1 to receive atorvastatin 40 mg/day or not in addition to interferon beta-1b until month 15. The primary endpoint was the proportion of patients with new lesions on T2-weighted images at month 15 compared to baseline at month three. At study end, the proportion of patients with new lesions on T2-weighted images was equal in both groups (odds ratio 1.14; 95 % CI 0.36–3.56; p = 0.81). All predefined secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of new Gd-enhancing lesions on T1-weighted images, total brain volume, volume of grey matter, volume of white matter, EDSS, MSFC, relapse rate, time to first relapse, number of relapse-free patients and neutralizing antibodies did not show any significant differences (all p values >0.1). Transient elevations of liver enzymes were more frequent with atorvastatin (p = 0.02). In conclusion, atorvastatin 40 mg/day in addition to interferon beta-1b did not have a beneficial effect on relapsing-remitting MS compared to interferon beta-1b monotherapy over a 12-month period.Keywords
This publication has 34 references indexed in Scilit:
- Vascular comorbidity is associated with more rapid disability progression in multiple sclerosisNeurology, 2010
- SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodologyTrials, 2009
- Effect of statins on clinical and molecular responses to intramuscular interferon beta-1aNeurology, 2009
- Comorbidity delays diagnosis and increases disability at diagnosis in MSNeurology, 2009
- Cross-validation of brain segmentation by SPM5 and SIENAXPsychiatry Research: Neuroimaging, 2008
- Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple SclerosisPLOS ONE, 2008
- Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepairFuture Neurology, 2008
- The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 2007
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Rating neurologic impairment in multiple sclerosisNeurology, 1983